NEWTON, Mass.--(BUSINESS WIRE)--Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company committed to bringing therapies that target mitochondrial dysfunction to patients with severe acute and chronic diseases, today announced that Travis Wilson, Chief Executive Officer, is presenting a corporate overview at Piper Jaffray’s 26th Annual Healthcare Conference.
The presentation will take place on Wednesday, December 3, 2014 at 10:50 a.m. EST at The New York Palace Hotel in New York, NY.
About Stealth BioTherapeutics
Stealth BioTherapeutics is a privately-held biopharmaceutical company committed to bringing mitochondria-targeted therapeutics to patients to treat both common and rare diseases. As the key common element in a variety of serious, debilitating diseases, mitochondria - the cell’s energy source - offer a promising yet untapped therapeutic target for diseases with significant unmet treatment needs. Stealth is developing its lead compounds Bendavia™ and Ocuvia™ in multiple therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases, and defining the broad potential of mitochondria-targeted therapies. Stealth’s promising pipeline of preclinical and clinical compounds is supported by more than 100 independent, peer-reviewed publications, abstracts and presentations.